<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321619</url>
  </required_header>
  <id_info>
    <org_study_id>VID-VAR-01/11</org_study_id>
    <nct_id>NCT01321619</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of the Use of Varicell Compared With Daflon</brief_title>
  <official_title>Study Clinical, Multicenter,Phase III,Prospective,Randomized,Comparative Double Blind/Double-dummy to Assess the Efficacy and Tolerability of the Use of Varicell in Reducing the Symptoms Caused by Chronic Venous Insufficiency and Hemorrhoidal Syndrome When Compared With Daflon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vidfarma Indústria de Medicamentos Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vidfarma Indústria de Medicamentos Ltda.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and tolerability of Varicell compared
      to Daflon, in reducing the symptoms caused by chronic venous insufficiency and hemorrhoidal
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy of Varicell compared with Daflon in the symptomatic treatment of
      chronic venous insufficiency and hemorrhoidal syndrome.

      To evaluate the tolerability of the use of Varicell compared with Daflon in the symptomatic
      treatment of chronic venous insufficiency and hemorrhoidal syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study to evaluate the efficacy and tolerability of the Use of Varicell Compared with Daflon.</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the efficacy of varicell compared with Daflon in the symptomatic treatment of chronic venous insufficiency and / or hemorrhoidal syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study to evaluate the efficacy and tolerability of the Use of Varicell Compared with Daflon.</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the tolerability of the use of Varicell when used for symptomatic treatment of chronic venous insufficiency and / or hemorrhoidal syndrome compared with Daflon.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Chronic Venous Insufficiency</condition>
  <condition>Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Varicell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug A(Varicell) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo daflon (Drug D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug D (Placebo Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daflon</intervention_name>
    <description>Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.</description>
    <arm_group_label>Varicell</arm_group_label>
    <other_name>Diosmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varicell placebo</intervention_name>
    <description>Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.</description>
    <arm_group_label>Placebo daflon (Drug D)</arm_group_label>
    <other_name>keratin</other_name>
    <other_name>Circanetten.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For both groups

          -  Patients who consent to participate in the study by signing the Instrument of Consent.

          -  Patients of all ethnic groups, of both sexes and aged at least 18 years old and
             maximum 65 years old;

          -  Being for seven days without any medication or treatment related to the venous system.

          -  Patients able to make proper use of medication;

        For Group V - Chronic Venous Insufficiency.

          -  Presence of at least two symptoms (pain, heaviness and discomfort) in the lower limbs
             with scores greater than 3 measured by visual analogue scale;

          -  Clinical diagnosis of varicose veins rating of 0 to 3 by CEAP;

        In Group H - hemorrhoidal syndrome.

          -  Presence of at least two symptoms (pain in the anorectal evacuation to walk and / or
             at rest, feeling of anal discomfort (burning, itching, irritation) to evacuate to walk
             and / or at rest, bloating in the anorectal region, the presence and intensity of
             bleeding in the anorectal region, the presence and intensity of mucus in the anorectal
             region) with a score equal to or greater than 3 measured by visual analogue scale;

          -  Clinical Diagnosis of Hemorrhoids grade 1 and grade 2.

        Exclusion Criteria:

        Pregnant or lactating;

          -  Patients aged less than 18 years old or older than 65 years old;

          -  Patients with a history of hypersensitivity to any component of the formula;

          -  Use of medications phlebotonics in the last 7 days;

          -  previous venous surgery;

          -  Patients with renal and liver failure.

          -  Patients with gastritis or gastric ulcer;

          -  Patients with acute inflammatory diseases of the bowel, intestinal obstruction,
             appendicitis;

          -  Patients with ileus, stenosis, atony, undiagnosed abdominal symptoms, colonopathy
             inflammatory abdominal pain of unknown cause dehydration and loss of water and
             electrolytes and constipation;

          -  Patients with blood coagulation disorders;

          -  Any condition which in the opinion of the physician investigator is significant and
             can make the patient unsuitable for study or that might put you under additional risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Waisberg, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>ABC School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Campos Júnior, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edmundo Vasconcelos Hospital Teacher</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laércio Robles, Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santa Marcelina Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelo Calil, Investigator</last_name>
    <phone>55 11 5549-6488</phone>
    <email>mcburihan@osite.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mônica Gonçalves, Coordenator</last_name>
    <phone>55 11 2070-6238</phone>
    <email>monica_monica0001@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Santa Marcelina Hospital</name>
      <address>
        <city>São Paulo</city>
        <zip>05016-081</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcelo Calil, Investigator</last_name>
      <phone>55 11 2070-6238</phone>
      <email>mcburihan@osite.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Mônica Gonçalves, Coordenator</last_name>
      <phone>55 11 2070-6238</phone>
      <email>monica_monica0001@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Walter Campos Junior, Investigator</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laércio Robles, Investigator</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques Waisberg, Investigator</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>June 13, 2011</last_update_submitted>
  <last_update_submitted_qc>June 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Vidfarma Indústria de Medicamentos Ltda.</name_title>
    <organization>Industry</organization>
  </responsible_party>
  <keyword>Chronic venous insufficiency</keyword>
  <keyword>Hemorrhoidal syndrome</keyword>
  <keyword>Varicell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

